Pfizer Jumps At The Chance To Apply Bind’s Technology To Immuno-Oncology
Bind has agreed to sell all of its assets to Pfizer for $19.75m after filing for bankruptcy in May. An auction is scheduled for July 25 if other bidders come forward.
You may also be interested in...
Serial entrepreneur Michael Gilman has taken the helm of another start-up; after selling Padlock to Bristol-Myers and Stromedix to Biogen, his new company Arrakis has raised a $38m Series A round with big biopharma backing.
Pfizer Inc. has made its first M&A move since the planned mega-deal with Allergan PLC collapsed. The big pharma announced May 16 that it will buy Anacor Pharmaceuticals Inc. for $99.25 per share in cash, or approximately $5.2bn.